Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

被引：7

作者：

Richardson, Paul G. ^{[1
]}

Sandhu, Irwindeep ^{[2
]}

Hofmeister, Craig C. ^{[3
]}

Orlowski, Robert Z. ^{[4
]}

White, Darrell ^{[5
,6
]}

Belotti, Angelo ^{[7
]}

Hansen, Charlotte Toftmann ^{[8
]}

Raje, Noopur S. ^{[9
]}

Chow, Tracy T. ^{[10
]}

Zhou, Zehua ^{[10
]}

Civardi, Tiziana ^{[11
]}

Koo, Phillip ^{[10
]}

Zhu, Yue ^{[10
]}

Katz, Jessica ^{[10
]}

Oriol, Albert ^{[12
,13
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Cross Canc Inst, Edmonton, AB, Canada

[3] Winship Canc Inst Emory Univ, Atlanta, GA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[7] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[8] Odense Univ Hosp, Odense, Denmark

[9] Massachusetts Gen Hosp, Boston, MA USA

[10] Bristol Myers Squibb, Princeton, NJ USA

[11] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

[12] Hosp Germans Trias i Pujol, Catalan Inst Oncol, Badalona, Spain

[13] Hosp Germans Trias i Pujol, Josep Carreras Inst, Badalona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174443

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
van de Donk, Niels
White, Darrell
Lipe, Brea
Khan, Abdullah
Niesvizky, Ruben
Oriol, Albert
Mesa, Mercedes Gironella
Anwer, Faiz
Bhutani, Manisha
McClune, Brian
Singhal, Seema
Cheng, Yiming
Hamada, Izumi
Jin, Kexin
Solomon, Thomas
Hong, Kevin
Amin, Alpesh
Maciag, Paulo
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S214 - S215
[22] Final results for the 1703 phase 1b/2 study of Elotuzumab (Elo) in combination with Lenalidomide (Len) and dexamethasone (dex) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Raab, M. S.
Richardson, P. G.
Jagannath, S.
Moreau, P.
Jakubowiak, A. J.
Facon, T.
Vij, R.
White, D.
Reece, D. E.
Benboubker, L.
Zonder, J.
Tsao, L. C.
Anderson, K. C.
Bleickardt, E.
Singhal, A. K.
Lonial, S.
Oncology Research and Treatment, 2015, 38 : 165 - 165
[23] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients with relapsed/refractory multiple myeloma (RRMM)
Weisel, K.
Knop, S.
Lonial, S.
Richardson, P. G.
Popat, R.
Stadtmauer, E. A.
Larsen, J. T.
Oriol, A.
Jagannath, S.
Cook, G.
Badros, A. Z.
Otero, Rodriguez P.
Siegel, D. S.
Nguyen, T., V
Di Micco, A.
Amin, A.
Chen, M.
Kueenburg, E.
van de Donk, N. W. C. J.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 86 - 87
[24] Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM).
Shank, Brandon R.
Primeaux, Brian
Horowitz, Sandra B.
Yeung, Erin K.
Lee, Irene Y.
Kaufman, Gregory Peter
Lee, Hans Chulhee
Manasanch, Elisabet Esteve
Patel, Krina K.
Orlowski, Robert Z.
Weber, Donna M.
Thomas, Sheeba K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.
Dholaria, Bhagirathbhai R.
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Hartmut
Martin, Thomas G.
Morillo, Daniel
Reece, Donna Ellen
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar J.
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, Marie-Anne Damiette
Wasch, Ralph
van de Donk, Niels W. C. J.
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
Sonneveld, Pieter
Terpos, Evangelos
Dimopoulos, Meletios A.
Ukropec, Jon
Smith, Elena
Houkes, Nienke
Schecter, Jordan Mark
Kastritis, Efstathios
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
Lonial, Sagar
Popat, Rakesh
Hulin, Cyrille
Jagannath, Sundar
Oriol, Albert
Richardson, Paul G.
Facon, Thierry
Weisel, Katja
Larsen, Jeremy T.
Minnema, Monique C.
Abdallah, Al-Ola
Badros, Ashraf Z.
Knop, Stefan
Stadtmauer, Edward A.
Chen, Min
Nguyen, Tuong Vi
Amin, Alpesh
Kueenburg, Elisabeth
Peluso, Teresa
van de Donk, Niels W. C. J.
BLOOD, 2021, 138
[28] Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN plus DEX) vs LEN plus DEX in relapsed/refractory multiple myeloma (R/R MM).
Alsaid, Nimer
McBride, Ali
Agarwal, Amit Balkrishna
Mutairi, Abdulaali
Anwer, Faiz
Abraham, Ivo
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29] Real-world outcomes of sequencing elotuzumab (elo)-based regimens following daratumumab (dara) in patients with relapsed/refractory multiple myeloma: results from the Connect® MM Registry
Ailawadhi, Sikander
Durie, Brian
Narang, Mohit
Omel, James
Wagner, Lynne
Toomey, Kathleen
Terebelo, Howard
Lee, Hans
Abonour, Rafat
Gasparetto, Cristina
Rifkin, Robert
Hardin, James
Lee, Kim
Dhanasiri, Sujith
Gentili, Christian
Yu, Edward
Jou, Ying-Ming
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S161 - S161
[30] First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G.
Vangsted, Annette J.
Ramasamy, Karthik
Trudel, Suzanne
Martinez, Joaquin
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Lonial, Sagar
Popat, Rakesh
Oriol, Albert
Karanes, Chatchada
Orlowski, Robert Z.
Berdeja, Jesus G.
Wong, Lilly
Shi, Chenyang
Lamba, Manisha
Barnett, Evelyn
Pierce, Daniel W.
Pourdehnad, Michael
Bahlis, Nizar J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →